Vascular Closure Devices Global Market - Forecast to 2022

Publishing Date : February, 2016
Report Code : HCMD0132
Price:
Single license $4,500
Site license $6,300
Global license $9,000


Note: The report would be dispatched after confirmation of payment

Vascular closure devices are used for achieving haemostasis in small holes in the blood vessels catheterization to reduce access site complications. Devices like plugs, suture mediated devices, clips, compression devices and hemostatic pads are used minimize the risk of bleeding and reduce the ambulation time. The vascular closure device global market is segmented by product type, access, intervention and geography. Products are sub segmented into active and passive approximator products. Under the active approximators there are clips, suture mediated devices, and plugs. Plugs market is again classified into FISH, collagen based and polymer based. Under the passive approximators there are hemostatic pads and compression devices. By intervention the vascular closure markets are divided into diagnostic and therapeutic. Based on the access site the market is segmented into femoral access and radial access.

Among the vascular closure products, the active approximators market dominated the products market by occupying a largest share in 2015. At the same time, the passive approximators market is also expected to grow at a high single digit CAGR from 2015 to 2022. Geographical wise North America is the largest market, followed by Europe and Asia Pacific. The North America regions suggest an array of opportunities for growth and are likely to be getting into the eyes of new investors in the vascular closure market. Growth is attributed to rising prevalence of lifestyle diseases and government initiatives in establishing innovative technologies and demand for sophisticated medical services.

The Vascular closure market is expected to grow steadily in the forecast period. The factors driving the growth of this market are increasing catheterization related procedures (PCI), preference for minimally-invasive solutions & rise in vascular procedures. Ease in usage and quick hemostatic properties of VCDs and increased utilization of transradial arterial access are some of the opportunities that are propelling the growth of the market. High price of products, complications associated with VCD, less adoption of novel technologies in emerging countries are hampering the market of vascular closure. Reduced reimbursement, usage of animal related sources and lower revenue potential of VCD are threats for the market growth.

Some of the key players of the vascular closure market are Abbott Laboratories (U.S.), Advanced Vascular Dynamics (U.S.), B Braun Melsungen AG (Germany), Biotronik Corpotation (Germany), C R Bard International (U.S.), Cardinal Health (U.S.), Cardiva medical (U.S.), Morris Innovative (U.S.), Scion Biomedical (U.S.), St Jude Medical (U.S.), Terumo Corporation (Japan) and Vascular Solutions, Inc (U.S.)

The report provides an in depth market analysis of the above mentioned segments across the following regions:

  • North America
  • Europe
  • Asia-Pacific 
  • Rest of the World (RoW)
  • 1     EXECUTIVE SUMMARY
  • 2     INTRODUCTION
    • 2.1     KEY TAKE AWAYS
    • 2.2     REPORT DESCRIPTION
    • 2.3     MARKETS COVERED
    • 2.4     STAKEHOLDERS
    • 2.5     RESEARCH METHODOLOGY
      • 2.5.1     MARKET SIZE ESTIMATION
      • 2.5.2     MARKET CRACKDOWN AND DATA TRIANGULATION
      • 2.5.3     SECONDARY SOURCES
      • 2.5.4     PRIMARY SOURCES
      • 2.5.5     KEY DATA POINTS FROM SECONDARY SOURCES
      • 2.5.6     KEY DATA POINTS FROM PRIMARY SOURCES
      • 2.5.7     ASSUMPTIONS
  • 3     MARKET ANALYSIS
    • 3.1     INTRODUCTION
    • 3.2     MARKET SEGMENTATION
    • 3.3     FACTORS INFLUENCING MARKET
      • 3.3.1     DRIVERS AND OPPORTUNITIES
        • 3.3.1.1     INCREASING CATHETERIZATION RELATED PROCEDURES
        • 3.3.1.2     PREFERENCE FOR MINIMALLY-INVASIVE SOLUTIONS
        • 3.3.1.3     EASE IN USAGE AND QUICK HEMOSTATIC PROPERTIES OF VCDS
        • 3.3.1.4     INCREASED UTILIZATION OF TRANSRADIAL ARTERIAL ACCESS
      • 3.3.2     RESTRAINTS AND THREATS
        • 3.3.2.1     HIGH PRICE OF PRODUCTS
        • 3.3.2.2     COMPLICATIONS ASSOCIATED WITH VCD
        • 3.3.2.3     LESS ADOPTION OF NOVEL TECHNOLOGIES IN EMERGING COUNTRIES
        • 3.3.2.4     REDUCED REIMBURSEMENT
        • 3.3.2.5     USAGE OF ANIMAL RELATED SOURCES
        • 3.3.2.6     LOWER REVENUE POTENTIAL OF VCD
    • 3.4     PORTER'S FIVE FORCE ANALYSIS
      • 3.4.1     THREAT OF NEW ENTRANTS
      • 3.4.2     THREAT OF SUBSTITUTES
      • 3.4.3     BARGAINING POWER OF SUPPLIERS
      • 3.4.4     BARGAINING POWER OF BUYERS
      • 3.4.5     COMPETITIVE RIVALRY
    • 3.5     REGULATORY AFFAIRS
      • 3.5.1     U.S.
      • 3.5.2     EUROPE
      • 3.5.3     INDIA
      • 3.5.4     CHINA
      • 3.5.5     JAPAN
    • 3.6     REIMBURSEMENT SCENARIO
      • 3.6.1     TRANSCATHETER EMBOLIZATION OR OCCLUSION SERVICES
      • 3.6.2     THROMBOLYSIS
      • 3.6.3     DIAGNOSTIC CARDIAC CATHETERIZATION
      • 3.6.4     INJECTION DIAGNOSTIC CARDIAC CATHETERIZATION
    • 3.7     UPCOMING TECHNOLOGIES
    • 3.8     SUPPLY CHAIN ANALYSIS
    • 3.9     MARKET SHARE ANALYSIS BY MAJOR PLAYERS
    • 3.1     PATENT TRENDS
  • 4     VASCULAR CLOSURE DEVICES GLOBAL MARKET, BY TYPE
    • 4.1     INTRODUCTION
    • 4.2     ACTIVE APPROXIMATORS
      • 4.2.1     CLIPS
      • 4.2.2     SUTURE MEDIATED DEVICES
      • 4.2.3     PLUGS
        • 4.2.3.1     COLLAGEN BASED
        • 4.2.3.2     POLYMER BASED
        • 4.2.3.3     FISH
    • 4.3     PASSIVE APPROXIMATORS
      • 4.3.1     HEMOSTATIC PADS/PATCHES
      • 4.3.2     COMPRESSION DEVICES
  • 5     VASCULAR CLOSURE DEVICES GLOBAL MARKET, BY INTERVENTION
    • 5.1     INTRODUCTION
    • 5.2     DIGNOSTICS
    • 5.3     THERAPEUTICS
  • 6     VASCULAR CLOSURE DEVICES GLOBAL MARKET, BY ACCESS
    • 6.1     INTRODUCTION
    • 6.2     FEMORAL ACCESS
    • 6.3     RADIAL ACCESS
  • 7     VASCULAR CLOSURE DEVICES GLOBAL MARKET, BY GEOGRAPHY
    • 7.1     INTRODUCTION
    • 7.2     NORTH AMERICA
    • 7.3     EUROPE
    • 7.4     ASIA PACIFIC
    • 7.5     REST OF THE WORLD
  • 8     COMPANY DEVELOPMENTS
    • 8.1     INTRODUCTION
    • 8.2     ACQUISITION AS A MAJOR GROWTH STRATEGY OF ACTIVE PHARMACEUTICAL INGREDIENTS MARKET PLAYERS
    • 8.3     MERGERS AND ACQUISITION
    • 8.4     AGREEMENTS PARTERNER SHIPS, COLLABORATIONS & JOINT VENTURES
    • 8.5     APPROVALS
    • 8.6     BUSINESS EXPANSION
    • 8.7     NEW PRODUCT LAUNCH
  • 9     COMPANY PROFILES
    • 9.1     ABBOTT LABORATORIES
      • 9.1.1     OVERVIEW
      • 9.1.2     FINANCIALS
      • 9.1.3     PRODUCT PORTFOLIO
      • 9.1.4     KEY DEVELOPMENTS
      • 9.1.5     BUSINESS STRATEGY
      • 9.1.6     SWOT ANALYSIS
    • 9.2     ADVANCED VASCULAR DYNAMICS
      • 9.2.1     OVERVIEW
      • 9.2.2     FINANCIALS
      • 9.2.3     PRODUCT PORTFOLIO
      • 9.2.4     KEY DEVELOPMENTS
      • 9.2.5     BUSINESS STRATEGY
      • 9.2.6     SWOT ANALYSIS
    • 9.3     B. BRAUN MELSUNGEN AG
      • 9.3.1     OVERVIEW
      • 9.3.2     FINANCIALS
      • 9.3.3     PRODUCT PORTFOLIO
      • 9.3.4     KEY DEVELOPMENTS
      • 9.3.5     BUSINESS STRATEGY
      • 9.3.6     SWOT ANALYSIS
    • 9.4     BIOTRONIK SE & CO. KG
      • 9.4.1     OVERVIEW
      • 9.4.2     FINANCIALS
      • 9.4.3     PRODUCT PORTFOLIO
      • 9.4.4     KEY DEVELOPMENTS
      • 9.4.5     BUSINESS STRATEGY
      • 9.4.6     SWOT ANALYSIS
    • 9.5     C.R.BARD INC.
      • 9.5.1     OVERVIEW
      • 9.5.2     FINANCIALS
      • 9.5.3     PRODUCT PORTFOLIO
      • 9.5.4     KEY DEVELOPMENTS
      • 9.5.5     BUSINESS STRATEGY
      • 9.5.6     SWOT ANALYSIS
    • 9.6     CARDINAL HEALTH INC.
      • 9.6.1     OVERVIEW
      • 9.6.2     FINANCIALS
      • 9.6.3     PRODUCT PORTFOLIO
      • 9.6.4     KEY DEVELOPMENTS
      • 9.6.5     BUSINESS STRATEGY
      • 9.6.6     SWOT ANALYSIS
    • 9.7     CARDIVA MEDICALS, INC.
      • 9.7.1     OVERVIEW
      • 9.7.2     FINANCIALS
      • 9.7.3     PRODUCT PORTFOLIO
      • 9.7.4     KEY DEVELOPMENTS
      • 9.7.5     BUSINESS STRATEGY
      • 9.7.6     SWOT ANALYSIS
    • 9.8     MORRIS INNOVATIVE, INC.
      • 9.8.1     OVERVIEW
      • 9.8.2     FINANCIALS
      • 9.8.3     PRODUCT PORTFOLIO
      • 9.8.4     KEY DEVELOPMENTS
      • 9.8.5     BUSINESS STRATEGY
      • 9.8.6     SWOT ANALYSIS
    • 9.9     SCION BIOMEDICALS, INC.
      • 9.9.1     OVERVIEW
      • 9.9.2     FINANCIALS
      • 9.9.3     PRODUCT PORTFOLIO
      • 9.9.4     KEY DEVELOPMENTS
      • 9.9.5     BUSINESS STRATEGY
      • 9.9.6     SWOT ANALYSIS
    • 9.10     ST.JUDE MEDICAL
      • 9.10.1     OVERVIEW
      • 9.10.2     FINANCIALS
      • 9.10.3     PRODUCT PORTFOLIO
      • 9.10.4     KEY DEVELOPMENTS
      • 9.10.5     BUSINESS STRATEGY
      • 9.10.6     SWOT ANALYSIS
    • 9.11     TERUMO CORPORATION
      • 9.11.1     OVERVIEW
      • 9.11.2     FINANCIALS
      • 9.11.3     PRODUCT PORTFOLIO
      • 9.11.4     KEY DEVELOPMENTS
      • 9.11.5     BUSINESS STRATEGY
      • 9.11.6     SWOT ANALYSIS
    • 9.12     VASCULAR SOLUTIONS INC.
      • 9.12.1     OVERVIEW
      • 9.12.2     FINANCIALS
      • 9.12.3     PRODUCT PORTFOLIO
      • 9.12.4     KEY DEVELOPMENTS
      • 9.12.5     BUSINESS STRATEGY
      • 9.12.6     SWOT ANALYSIS

      LIST OF TABLES

      • TABLE 1     VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 2     VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 3     VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE, BY INTERVENTION, (2014-2022) ($MN)
      • TABLE 4     VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE, BY ACCESS, (2014-2022) ($MN)
      • TABLE 5     VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 6     ACTIVE APPROXIMATOR GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 7     ACTIVE APPROXIMATOR GLOBAL MARKET REVENUE, BY PRODUCT, (2015-2022) ($MN)
      • TABLE 8     CLIPS GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 9     SUTURE MEDIATED DEVICES GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 10     PLUGS GLOBAL MARKET REVENUE, BY MATERIAL, (2014-2022) ($MN)
      • TABLE 11     PLUGS GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 12     COLLAGEN BASED PLUGS GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 13     POLYMER BASED PLUGS GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 14     PASSIVE APPROXIMATOR GLOBAL MARKET REVENUE, BY PRODUCT, (2014-2022) ($MN)
      • TABLE 15     PASSIVE APPROXIMATOR GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 16     HEMOSTATIC PADS/PATCHES GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 17     COMPRESSION DEVICES GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 18     VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE, BY INTERVENTION, (2014-2022) ($MN)
      • TABLE 19     DIAGNOSTICS VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 20     THERAPEUTICS VASCULAR CLOSURE GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 21     VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE, BY ACCESS, (2014-2022) ($MN)
      • TABLE 22     FEMORAL VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 23     RADIAL VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN)
      • TABLE 24     NORTH AMERICAN VASCULAR CLOSURE DEVICES MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 25     NORTH AMERICAN ACTIVE APPROXIMATOR MARKET REVENUE, BY PRODUCT, (2014-2022) ($MN)
      • TABLE 26     NORTH AMERICAN PLUGS MARKET REVENUE, BY MATERIAL, (2014-2022) ($MN)
      • TABLE 27     NORTH AMERICAN PASSIVE APPROXIMATOR MARKET REVENUE, BY PRODUCT, (2014-2022) ($MN)
      • TABLE 28     NORTH AMERICAN VASCULAR CLOSURE DEVICES MARKET REVENUE, BY INTERVENTION, (2014-2022) ($MN)
      • TABLE 29     NORTH AMERICAN VASCULAR CLOSURE DEVICE MARKET REVENUE, BY ACCESS, (2014-2022) ($MN)
      • TABLE 30     EUROPEAN VASCULAR CLOSURE DEVICES MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 31     EUROPEAN ACTIVE APPROXIMATOR MARKET REVENUE, BY PRODUCT, (2014-2022) ($MN)
      • TABLE 32     EUROPEAN PLUGS MARKET REVENUE, BY MATERIAL, (2014-2022) ($MN)
      • TABLE 33     EUROPEAN PASSIVE APPROXIMATOR MARKET REVENUE, BY PRODUCT, (2014-2022) ($MN)
      • TABLE 34     EUROPEAN VASCULAR CLOSURE DEVICES MARKET REVENUE, BY INTERVENTION, (2014-2022) ($MN)
      • TABLE 35     EUROPEAN VASCULAR CLOSURE DEVICES MARKET REVENUE, BY ACCESS, (2014-2022) ($MN)
      • TABLE 36     ASIA-PACIFIC VASCULAR CLOSURE DEVICES MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 37     ASIA-PACIFIC ACTIVE APPROXIMATOR MARKET REVENUE, BY PRODUCT, (2014-2022) ($MN)
      • TABLE 38     ASIA-PACIFIC PLUGS MARKET REVENUE, BY MATERIAL, (2014-2022) ($MN)
      • TABLE 39     ASIA-PACIFIC PASSIVE APPROXIMATOR MARKET REVENUE, BY PRODCUT, (2014-2022) ($MN)
      • TABLE 40     ASIA-PACIFIC VASCULAR CLOSURE DEVICES MARKET REVENUE, BY INTERVENTION, (2014-2022) ($MN)
      • TABLE 41     ASIA-PACIFIC VASCULAR CLOSURE DEVICES MARKET REVENUE, BY ACCESS, (2014-2022) ($MN)
      • TABLE 42     ROW VASCULAR CLOSURE DEVICES MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • TABLE 43     ROW ACTIVE APPROXIMATOR MARKET REVENUE, BY PRODUCT, (2014-2022) ($MN)
      • TABLE 44     ROW PLUGS MARKET REVENUE, BY MATERIAL, (2014-2022) ($MN)
      • TABLE 45     ROW PASSIVE APPROXIMATOR MARKET REVENUE, BY PRODUCT, (2014-2022) ($MN)
      • TABLE 46     ROW VASCULAR CLOSURE DEVICES MARKET REVENUE, BY INTERVENTION, (2014-2022) ($MN)
      • TABLE 47     ROW VASCULAR CLOSURE DEVICES MARKET REVENUE, BY ACCESS, (2014-2022) ($MN)
      • TABLE 48     MERGERS AND ACQUISITION (2011-2015)
      • TABLE 49     AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES (2012-2015)
      • TABLE 50     APPROVALS (2011-2015)
      • TABLE 51     BUSINESS EXPANSION (2011-2015)
      • TABLE 52     NEW PRODUCT LAUNCH (2011-2015)
      • TABLE 53     ABBOTT LABORATORIES: TOTAL REVENUE AND R&D EXPENSES, (2013-2015) ($MN)
      • TABLE 54     ABBOTT LABORATORIES: TOTAL REVENUE, BY SEGMENT, (2013-2015) ($MN)
      • TABLE 55     ABBOTT LABORATORIES: TOTAL REVENUE, BY GEOGRAPHY, (2013-2015) ($MN)
      • TABLE 56     B.BRAUN MELSUNGEN AG: TOTAL REVENUE AND R&D EXPENSES, (2012-2014) ($MN)
      • TABLE 57     B.BRAUN MELSUNGEN AG: TOTAL REVENUE, BY SEGMENT, (2012-2014) ($MN)
      • TABLE 58     B.BRAUN MELSUNGEN AG: TOTAL REVENUE, BY GEOGRAPHY, (2012-2014) ($MN)
      • TABLE 59     C.R.BARD INC.: TOTAL REVENUE AND R&D EXPENSES (2013-2015) ($MN)
      • TABLE 60     C.R.BARD INC: TOTAL REVENUE, BY SEGMENT, (2013-15) ($MN)
      • TABLE 61     C.R.BARD INC: TOTAL REVENUE, BY REGION, (2013-15) ($MN)
      • TABLE 62     CARDINAL HEALTH, INC.: TOTAL REVENUE AND OPERATING EXPENSES, (2013-2015) ($MN)
      • TABLE 63     CARDINAL HEALTH, INC.: TOTAL REVENUE, BY SEGMENT, (2013-2015) ($MN)
      • TABLE 64     CARDINAL HEALTH, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2013-2015) ($MN)
      • TABLE 65     ST JUDE MEDICAL: TOTAL REVENUE AND R&D EXPENSES, (2013-2015) ($MN)
      • TABLE 66     ST JUDE MEDICAL : TOTAL REVENUE, BY SEGMENT, (2013-2015) ($MN)
      • TABLE 67     ST.JUDE INC.: TOTAL REVENUE, BY GEOGRAPHY, (2013-2015) ($MN)
      • TABLE 68     TERUMO CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2013-2015) ($MN)
      • TABLE 69     TERUMO CORPORATION: TOTAL REVENUE, BY SEGMENTS, (2013-2015) ($MN)
      • TABLE 70     TERUMO CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2013-2015) ($MN)
      • TABLE 71     VASCULAR SOLUTIONS INC.: TOTAL REVENUE AND R&D EXPENSES, (2013-2015) ($MN)
      • TABLE 72     VASCULAR SOLUTIONS INC.: TOTAL REVENUE, BY SEGMENT, (2013-2015) ($MN)
      • TABLE 73     VASCULAR SOLUTIONS INC.: TOTAL REVENUE, BY GEOGRAPHY, (2013-2015) ($MN)

      LIST OF FIGURES

      • FIGURE 1     VASCULAR CLOSURE DEVICE GLOBAL MARKET SHARE, BY GEOGRAPHY, (2014-22) ($MN)
      • FIGURE 2     RESEARCH METHODOLOGY: VASCULAR CLOSURE DEVICES MARKET
      • FIGURE 3     VASCULAR CLOSURE DEVICES MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
      • FIGURE 4     VASCULAR CLOSURE DEVICES MARKET: FORECASTING MODEL
      • FIGURE 5     VASCULAR CLOSURE DEVICES MARKET: MARKET CRACHDOWN AND DATA TRIANGULATION
      • FIGURE 6     VASCULAR CLOSURE DEVICES MARKET: MARKET SEGMENTATION
      • FIGURE 7     MARKET DYNAMICS
      • FIGURE 8     VASCULAR CLOSURE DEVICES MARKET: PORTER'S ANALYSIS
      • FIGURE 9     VASCULAR CLOSURE DEVICE MARKET: SUPPLY CHAIN ANALYSIS
      • FIGURE 10     VASCULAR CLOSURE DEVICES GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2015 (%)
      • FIGURE 11     VASCULAR CLOSURE DEVICES MARKET: PATENT FILING BY MAJOR PLAYERS (2011-2015)
      • FIGURE 12     VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE, BY TYPE, (2014-2022) ($MN)
      • FIGURE 13     ACTIVE APPROXIMATOR GLOBAL MARKET REVENUE, BY PRODUCT, 2015, ($MN)
      • FIGURE 14     PASSIVE APPROXIMATOR GLOBAL MARKET REVENUE, BY PRODUCT, (2014-2022), ($MN)
      • FIGURE 15     VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE, BY INTERVENTION, (2014-22) ($MN)
      • FIGURE 16     VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE, BY ACCESS, (2015 V'S 2022) ($MN)
      • FIGURE 17     RADIAL ACCESS DEVICES GLOBAL MARKET SHARE, BY REGION, 2015, (%)
      • FIGURE 18     VASCULAR CLOSURE DEVICES GLOBAL MARKET REVENUE, BY REGION, (2014-2022) ($MN) (CAGR %)
      • FIGURE 19     NORTH AMERICAN VASCULAR CLOSURE DEVICES MARKET REVENUE, BY TYPE, INTERVENTION & ACCESS, (2015 V'S 2022) ($MN)
      • FIGURE 20     EUROPEAN VASCULAR CLOSURE DEVICES MARKET REVENUE, BY TYPE, INTERVENTION & ACCESS, (2015 V'S 2022) ($MN)
      • FIGURE 21     ASIA-PACIFIC VASCULAR CLOSURE DEVICES MARKET REVENUE, BY TYPE, INTERVENTION & ACCESS, (2015 V'S 2022) ($MN)
      • FIGURE 22     ROW VASCULAR CLOSURE DEVICES MARKET REVENUE, BY TYPE, INTERVENTION & ACCESS, (2015 V'S 2022) ($MN)
      • FIGURE 23     KEY GROWTH STRATEGIES (2012-2015)
      • FIGURE 24     SWOT: ABBOTT LABORATORIES
      • FIGURE 25     SWOT: ADVANCED VASCULAR DYNAMICS
      • FIGURE 26     SWOT: B.BRAUN MELSUNGEN AG
      • FIGURE 27     SWOT: BIOTRONIK SE & CO. KG
      • FIGURE 28     SWOT: C.R.BARD INC.
      • FIGURE 29     SWOT: CARDINAL HEALTH, INC.
      • FIGURE 30     SWOT: CARDIVA MEDICALS, INC.
      • FIGURE 31     SWOT: MORRIS INNOVATIVE MEDICALS, CORP.
      • FIGURE 32     SWOT: SCION BIOMEDICAL, INC.
      • FIGURE 33     SWOT: ST.JUDE MEDICAL
      • FIGURE 34     SWOT: TERUMO CORPORATION
      • FIGURE 35     SWOT: VASCULAR SOLUTIONS INC.